Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Beam Therapeutics Inc. (BEAM) reported revenue of $490K in Q2 2026 (quarter ended Jun 30, 2026), down 94% from the same quarter a year earlier. That came with net loss of $123M. For the full year FY2025, revenue was $140M (+120% year on year) and net income −$80M.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.